These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36150809)

  • 1. Pharmacologic Management of Excessive Daytime Sleepiness.
    Ono T; Takenoshita S; Nishino S
    Sleep Med Clin; 2022 Sep; 17(3):485-503. PubMed ID: 36150809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic Management of Excessive Daytime Sleepiness.
    Takenoshita S; Nishino S
    Sleep Med Clin; 2020 Jun; 15(2):177-194. PubMed ID: 32386693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium oxybate improves excessive daytime sleepiness in narcolepsy.
    Black J; Houghton WC
    Sleep; 2006 Jul; 29(7):939-46. PubMed ID: 16895262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic Management of Excessive Daytime Sleepiness.
    Takenoshita S; Nishino S
    Sleep Med Clin; 2017 Sep; 12(3):461-478. PubMed ID: 28778242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea.
    Hoy SM
    CNS Drugs; 2023 Nov; 37(11):1009-1020. PubMed ID: 37847434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic Hypersomnia and Other Hypersomnia Syndromes.
    Trotti LM; Arnulf I
    Neurotherapeutics; 2021 Jan; 18(1):20-31. PubMed ID: 32901432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav
    Heo YA
    CNS Drugs; 2022 May; 36(5):541-549. PubMed ID: 35357671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia.
    Junnarkar G; Allphin C; Profant J; Steininger TL; Chen C; Zomorodi K; Skowronski R; Black J
    Expert Opin Drug Discov; 2022 Feb; 17(2):109-119. PubMed ID: 34818123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy.
    Thorpy MJ; Hyman D; Parks GS; Chen A; Foley C; Baldys B; Ito D; Singh H
    Clin Ther; 2022 Oct; 44(10):1356-1369. PubMed ID: 36171171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives.
    Abad VC
    Nat Sci Sleep; 2021; 13():75-91. PubMed ID: 33531850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
    Krief S; Berrebi-Bertrand I; Nagmar I; Giret M; Belliard S; Perrin D; Uguen M; Robert P; Lecomte JM; Schwartz JC; Finance O; Ligneau X
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00855. PubMed ID: 34423920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy.
    Pérez-Carbonell L
    Curr Treat Options Neurol; 2019 Nov; 21(11):57. PubMed ID: 31713736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Wake disorders. I. Primary wake disorders].
    Billiard M; Carlander B
    Rev Neurol (Paris); 1998 Feb; 154(2):111-29. PubMed ID: 9773032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on Persistent Excessive Daytime Sleepiness in OSA.
    Javaheri S; Javaheri S
    Chest; 2020 Aug; 158(2):776-786. PubMed ID: 32147246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy.
    Xyrem International Study Group
    J Clin Sleep Med; 2005 Oct; 1(4):391-7. PubMed ID: 17564408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solriamfetol for the Management of Excessive Daytime Sleepiness.
    Cuomo MC; Sheehan AH; Jordan JK
    J Pharm Pract; 2022 Dec; 35(6):963-970. PubMed ID: 33882756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy.
    Yang J; Gao J
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):723-728. PubMed ID: 31215815
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacological Interventions for Excessive Daytime Sleepiness in Adults with Narcolepsy: A Systematic Review and Network Meta-Analysis.
    Chien PY; Kuo CY; Lin MH; Chang YJ; Hung CC
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
    Sarfraz N; Okuampa D; Hansen H; Alvarez M; Cornett EM; Kakazu J; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(3):34222. PubMed ID: 35774905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.
    Maski K; Trotti LM; Kotagal S; Robert Auger R; Rowley JA; Hashmi SD; Watson NF
    J Clin Sleep Med; 2021 Sep; 17(9):1881-1893. PubMed ID: 34743789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.